Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor
Cancer letters, 2008•Elsevier
We have recently shown that despite of the fact that the ErbB2-positive JIMT-1 human breast
cancer cells intrinsically resistant to trastuzumab in vitro, trastuzumab inhibited the outgrowth
of early phase JIMT-1 xenografts in SCID mice via antibody-dependent cellular cytotoxicity
(ADCC). Here we show that trastuzumab significantly reduces the number of circulating and
disseminated tumor cells (CTCs and DTCs), in this xenograft model system at a time when
the primary tumor is already unresponsive to trastuzumab. This observation suggests that …
cancer cells intrinsically resistant to trastuzumab in vitro, trastuzumab inhibited the outgrowth
of early phase JIMT-1 xenografts in SCID mice via antibody-dependent cellular cytotoxicity
(ADCC). Here we show that trastuzumab significantly reduces the number of circulating and
disseminated tumor cells (CTCs and DTCs), in this xenograft model system at a time when
the primary tumor is already unresponsive to trastuzumab. This observation suggests that …
We have recently shown that despite of the fact that the ErbB2-positive JIMT-1 human breast cancer cells intrinsically resistant to trastuzumab in vitro, trastuzumab inhibited the outgrowth of early phase JIMT-1 xenografts in SCID mice via antibody-dependent cellular cytotoxicity (ADCC). Here we show that trastuzumab significantly reduces the number of circulating and disseminated tumor cells (CTCs and DTCs), in this xenograft model system at a time when the primary tumor is already unresponsive to trastuzumab. This observation suggests that ErbB2 positive CTCs and DTCs might be sensitive to trastuzumab-mediated ADCC even if when the primary tumor is already non-responsive. Thus, trastuzumab treatment might also be beneficial in the case of patients with breast cancer that is already trastuzumab resistant.
Elsevier
